Article

47 views
The global oncology mAb market is expected to reach around $45 billion by the end of this decade, and many big drugs will lose patent protection during this time. This makes immunology and oncology biosimilars a perfect space to enter for companies.  Furthermore, blockbuster drugs worth about $60 billion will go-off-patent in the US alone. This would push the current global biosimilar market of $2 billion to around $12 billion by 2020. Are you prepared to delve into this booming industry that holds high growth prospects? Read the article to get more insights about the biosimilars industry trends and future forecasts.
Authentic, Ad-free Reporting
High-quality, Exclusive Content
Original Market Research Reports
Original Resources & Databases
Global Surveys & Guidelines
Lowest Subscription Pricing

Healthcare News You Won't Read Elsewhere

Most up-to-date information, original and in-depth reviews, full-length exclusive market reports and forecasts, full-access to the smart knowledge base centres, useful resources and databases.

Access articles & resources worth up to $4000.

KEY POINTS The global oncology mAb market is expected to reach around $45 billion by the end of this decade. ...

You have read of your 8 free articles this month.

Subscribe to
Medgenera All-Access

Enjoy unlimited access to all contents, resources, exclusive market research reports, databases, surveys and many more features by subscribing to Medgenera All-Access.

Access articles & resources worth up to US $4, 000 per month.

Authentic, Ad-free Reporting
High-quality, Exclusive Content
Original Market Research Reports
Original Resources & Databases
Global Surveys & Guidelines
Lowest Subscription Pricing

Healthcare News You Won't Read Elsewhere

Most up-to-date information, original and in-depth reviews, full-length exclusive market reports and forecasts, full-access to the smart knowledge base centres, useful resources and databases.

Access articles & resources worth up to $4000.

More in NEWLY PUBLISHED


NEWLY PUBLISHED

2018 is the Make or Break Year for Bugworks Research: CEO

Bangalore-based Bugworks Research is the only biotech startup in Asia which received CARB-X funding to combat antibiotic resistance issue by developing new antibiotics candidate. Bugworks' CEO Dr. Anandkumar talked about his concern over the rising superbugs problem and his vision for Bugworks in 2018.

BRIEFING

FDA Approves Imfinzi for Not Advanced, Inoperable Lung Cancer

AstraZeneca’s bladder and lung cancer drug, Imfinzi® (durvalumab) received the US FDA approval for the expanded use of the drug ...

FUNDRAISE

3D Bioprinting Biotech Pandorum Raises $3.6 M, Aims to Reach Market

Bangalore-based 3D bioprinting startup, Pandorum Technologies has raised $3.6 million in the Series A funding round led by Indian Angel Network. Pandorum develops 3D printed human tissues for medical research and development. It has developed India’s first 3D-printed artificial human liver tissues in 2015 which mimic human liver tissue at structural and functional level. Continue reading...

BRIEFING

Sanofi’s Next-Generation Insulin, Toujeo Launches in India

Sanofi India launched its new product- Toujeo® (insulin glargine injection) in India. It is once-daily, long-acting basal insulin that improves blood sugar control in people with type 1 and types 2 diabetes. Continue reading...

Most Popular


GROW

7 New Ideas to Start a Healthcare Business in India (2018)

Healthcare in India is showing a gradual progress and there is an abundance of opportunity to create an evolving business by tackling the major challenges of the mass population. Herein, we are proposing the seven new healthcare business ideas in India in 2018 which are based on our observations of the current Indian market, its behavior, challenges, and opportunities.

MARKET INSIGHTS

9 Most Valuable Drugs Under Development (2018)

The top 9 drugs currently under research and developments are ranked based on their Net Present Value. These drugs are forecasted to be the future blockbuster. With $10,199 million Net Present Value, Aducanumab, the Ant-Alzheimer's investigational drug of Biogen is ranked as the topmost valued upcoming drug under development. Total Word Counts of the article: 782. Continue reading..